Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in August.
| PALO ALTO, Calif., Aug. 3, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in August.
Live webcasts of the BTIG fireside chat and Wedbush presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab. A replay of the webcast will be available approximately one hour following the live event. About Eiger Eiger’s lead programs target Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis. Eiger is developing two complementary treatments for HDV. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3. Eiger has filed an NDA and MAA for lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. FDA PDUFA date is November 20, 2020. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. Investors and Media: Sri Ryali
SOURCE Eiger BioPharmaceuticals, Inc. | ||
Company Codes: NASDAQ-NMS:EIGR |
View original content to download multimedia:
